Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ROSUVASTATINA/RAMIPRIL EGIS 20 MG/5 MG CÁPSULAS DURAS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ROSUVASTATINA/RAMIPRIL EGIS 20 MG/5 MG CÁPSULAS DURAS

Approved

STANDARD

ROSUVASTATINA/RAMIPRIL EGIS 20 MG/5 MG CÁPSULAS DURAS

Egis Pharmaceuticals Plc.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 12, 2022
Approval ID: 3622b01176109111
Company: Egis Pharmaceuticals Plc.
Type: Standard

Approval Details

Approval Id: 3622b01176109111
Drug Cima Aemps Name: ROSUVASTATINA/RAMIPRIL EGIS 20 MG/5 MG CÁPSULAS DURAS
Register Number: 86122
Holder Company Name: Egis Pharmaceuticals Plc.
Marketing Company Name: Egis Pharmaceuticals Plc.
Authorization Date: 2022-04-12
Dosage Form: CÁPSULA DURA
Dose: 20 mg/5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Egis Pharmaceuticals Plc.

Active Ingredients

ROSUVASTATINA CALCICA

20,84 mg

RAMIPRIL

5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 12, 2022

Approval ID

3622b01176109111

Type

Standard

Back to CIMA-AEMPS Approvals